German pharmaceutical firm BioNTech, one of the first companies worldwide to develop an effective coronavirus vaccine, is looking to acquire its domestic rival CureVac, the firm said on Thursday.

Senior Biden Food and Drug Administration (FDA) officials spent weeks casting doubt on reports of cardiac risks associated with the ...

Vaccinated patients hospitalized with COVID-19 who developed acute kidney injury had better outcomes than unvaccinated ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

(Reuters) -Pfizer and other drug companies have met with the Trump administration to discuss most-favored-nation pricing but ...

Pfizer is gearing up for a federal preemption defense, its first fight designed to wipe out more than 400 lawsuits over ...

Pfizer and other drug companies have met with the Trump administration to discuss most-favored-nation pricing but no commitments have been made, Chief Executive Albert Bourla said on Monday at an ...

Findings indicate that frequent COVID-19 booster shots do not weaken T-cell responses, alleviating concerns for vulnerable ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

What was holding up a deal appeared to be the lack of affordable units, as a previous proposal called for 420. However, NYC's ...